18 . July , 2019 - Thursday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Botulinum Toxin Type A

Big Image Pronouncation: (BOT-yoo-lin-um)
Class: Botulinum toxin, Ophthalmic surgical adjunct

Trade Names:
Botox
- Powder for injection 100 units vacuum-dried Clostridium botulinum toxin type A neurotoxin complex

Trade Names:
Botox Cosmetic
- Powder for injection 100 units vacuum-dried C. botulinum toxin type A neurotoxin complex

Mechanism of Action

Pharmacology

Blocks neuromuscular transmission by binding to acceptor sites on motor or sympathetic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine.

Produces temporary chemical denervation of sweat glands and local reduction in sweating when injected intradermally.

Pharmacokinetics

Absorption

Not expected to be present in peripheral blood at measurable levels following IM or intradermal injection at recommended doses.

Indications and Usage

Treatment of cervical dystonia in adults to decrease severity of abnormal head position and neck pain associated with cervical dystonia; treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorder in patients 12 yr of age and older; treatment of severe primary axillary hyperhidrosis inadequately managed with topical agents ( Botox ); for temporary improvement in appearance of moderate to severe glabellar lines associated with corrugator or procerus muscle activity in patients 65 yr of age or younger ( Botox Cosmetic ).

Contraindications

Infection at the proposed injection site(s).

Dosage and Administration

Axillary Hyperhidrosis ( Botox only)
Adults

Intradermally Inject 50 units (2 mL of reconstituted solution) intradermally into defined hyperhidrotic area in 0.1 to 0.2 mL aliquots to each axilla evenly distributed in multiple sites (10 to 15) approximately 1 to 2 cm apart. Administer repeat injections when clinical effect of previous injection diminishes.

Blepharospasm ( Botox only)
Adults and children 12 yr of age and older

IM Initially, inject 1.25 to 2.5 units (0.05 to 0.1 mL volume at each site) into the medial and lateral pretarsal orbicularis oculi of the upper lid and into the lateral pretarsal orbicularis oculi of the lower lid.

Cervical Dystonia ( Botox only)
Adults and children 16 yr of age and older

IM In patients with known history of tolerance, tailor dosing in initial and sequential treatments to the individual patient based on patient's head and neck position, localized pain, muscle hypertrophy, patient response, and adverse reaction history. In patients without prior use, use lower dose than in patients with known history of tolerance, adjusting subsequent doses based on individual response.

Glabellar Lines ( Botox Cosmetic only)
Adults (65 yr of age or younger)

IM Total treatment dose is 20 units in 0.5 mL at intervals no more frequently than every 3 mo (duration of activity of botulinum toxin type A is approximately 3 to 4 mo).

Strabismus ( Botox only)
Adults and children 12 yr of age and older

IM Inject between 0.05 to 0.15 mL per muscle into extraocular muscles utilizing electrical activity recorded from tip of injection needle as guide to placement within target muscle.

General Advice

  • Reconstitute powder for injection following manufacturer's guidelines for dilution using sterile, nonpreserved saline injection. Record date and time of reconstitution on vial.
  • Discard vial if vacuum does not pull diluent into vial.
  • Do not reconstitute with diluents other than sterile, nonpreserved saline, or add other medications to vial.
  • Do not administer if particulate matter, cloudiness, or discoloration noted.
  • Use a new, sterile needle and syringe to enter vial on each occasion for removal of medication. Epinephrine should be available or other precautionary method should an anaphylactic reaction occur.
  • Discard any unused solution that is not used within 4 h of reconstitution.
  • Follow institutional or organizational procedures for discarding medical waste and disposing unused solution, vials, and equipment used with the drug administration.
  • Do not exceed recommended dosages or frequencies of administration.

Storage/Stability

Store unopened vials in refrigerator (36° to 46°F). Reconstituted solution may be stored for up to 4 h if refrigerated. Do not freeze reconstituted solution.

Drug Interactions

Aminoglycosides, drugs interfering with neuromuscular transmission (eg, lincomycin, quinidine, succinylcholine)

The effects of botulinum toxin may be potentiated.

Botulinum neurotoxin

Administration of a different botulinum neurotoxin at the same time or within several months of each other may exacerbate excessive neuromuscular weakness.

Laboratory Test Interactions

None well documented.

Adverse Reactions

Cardiovascular

Hypertension (1%); arrhythmia; MI; syncope (postmarketing).

CNS

Anxiety, asthenia, dizziness, drowsiness, hypertonia (2% to 10%); headache (13%); dizziness, paresthesia (1%); malaise, vertigo with nystagmus (postmarketing).

Dermatologic

Pruritus, sweating (3% to 10%); erythema (2%); skin tightness (1%); skin rash (including erythema multiforme, psoriasiform eruption, urticaria) (postmarketing).

EENT

Eye dryness, superficial punctuate keratitis (6%); diplopia, pharyngitis, rhinitis (2% to 10%); blepharoptosis (3%); blurred vision, decreased hearing, ear noise, glaucoma, retinal vein occlusion (postmarketing).

GI

Dysphagia (19%); nausea, oral dryness (2% to 10%); dyspepsia, tooth disorder (1%); abdominal pain, diarrhea, loss of appetite, nausea, vomiting (postmarketing).

Genitourinary

UTI (1%).

Hematologic-Lymphatic

Ecchymosis (2%).

Local

Hemorrhage (3% to 10%); soreness (2% to 10%); bruising; tenderness; weakness; erythema, facial pain (less than 3%); pain and edema at injection site (2%); localized numbness (postmarketing).

Musculoskeletal

Neck pain (11%); back pain (2% to 10%); muscle weakness (2%); chest discomfort, myalgia, myasthenia gravis (postmarketing).

Respiratory

Upper respiratory infection (12%); cough, dyspnea (2% to 10%); pneumonia; infection (4%); bronchitis, sinusitis (2%).

Miscellaneous

Ptosis (21%); fever, infection, numbness, speech disorder, stiffness (2% to 10%); anaphylaxis; transient ptosis (5%); flu syndrome (2%); allergic reaction, brachial plexopathy, facial paralysis, fever (postmarketing).

Precautions

Pregnancy

Category C .

Lactation

Undetermined.

Children

Botox Cosmetic is not recommended for use in children.

Blepharospasm and strabismus

Safety and efficacy in children younger than 12 yr of age not established.

Cervical dystonia

Safety and efficacy in children younger than 16 yr of age not established.

Hyperhidrosis

Safety and efficacy in children younger than 18 yr of age not established.

Elderly

Use with caution, reflecting higher frequency of decreased hepatic, renal, or cardiac function and comorbidity.

Hypersensitivity

Serious and/or immediate hypersensitivity reactions have occurred.

Albumin

Because this product contains albumin, a derivative of human blood, it carries a remote risk of viral disease transmission.

Bleeding disorders

Use with caution in patients who have bleeding disorders or are taking anticoagulants.

Cardiovascular

Rare reports of CV adverse reactions, including arrhythmia and MI, some with fatal outcomes, have occurred.

Dermatologic

Use with caution in patients who have an inflammatory skin problem at injection site. Marked facial asymmetry, ptosis, dermatochalasis, deep dermal scarring, thick sebaceous skin, or when atrophy is present in the target muscles.

Dysphagia

Risk may be increased in patients requiring injections into the levator scapulae, patients with smaller neck muscle mass, and patients requiring bilateral injections into sternocleidomastoid muscle.

Immunogenicity

Treatment with botulinum toxin type A may cause formation of neutralizing antibodies that may reduce the efficacy of subsequent botulinum toxin type A treatments.

Neuropathic disorders

Use with caution in patients with peripheral motor neuropathic disease (eg, amyotrophic lateral sclerosis) or neuromuscular junctional disorders (eg, myasthenia gravis) because of increased risk of systemic effects, including dysphagia and respiratory compromise.

Ophthalmic

Retrobulbar hemorrhage has occurred from needle penetration into the orbit. Ocular penetrations also have occurred. Spatial disorientation, double vision, or past pointing may occur. Covering affected eye may alleviate these symptoms.

Reduced blinking

Reduced blinking from injection of the orbicularis muscle can lead to corneal exposure, persistent epithelial defect, and corneal ulceration.

Secondary hyperhidrosis

Evaluate patient for secondary causes of hyperhidrosis (eg, hyperthyroidism) before initiating therapy.

Overdosage

Symptoms

Muscle paralysis, systemic weakness.

Patient Information

  • Advise patient or caregiver that medication will be prepared and administered by a health care provider in a health care setting.
  • Advise patient being treated for cervical dystonia that improvement should occur within the first 2 wk following treatment, and max improvement should occur within about 6 wk. Advise patient that beneficial effects may last 3 mo before retreatment is needed.
  • Advise patient being treated for blepharospasm that improvement should occur within the first 3 days following treatment, and max improvement should occur within about 1 to 2 wk. Advise patient that beneficial effects may last 3 mo before retreatment is needed.
  • Advise patient being treated for strabismus that improvement should occur within the first 2 days following treatment, and max improvement should occur within the first week. Advise patient that beneficial effects may last 2 to 6 wk before the effects begin to wear off.
  • Advise patient being treated for glabellar lines that improvement should occur within the first 2 days following treatment, and max improvement should occur within the first week. Advise patient that beneficial effects may last 3 to 4 mo.
  • Advise patient or caregiver to immediately seek medical assistance if swallowing, speech, or breathing problems develop.
  • Advise patient to report intolerable injection site reactions or unusual symptoms to health care provider.
  • Caution sedentary patient to resume activity gradually following treatment with botulinum toxin.
  • Remind patient that office visits will be required to monitor therapy and to keep appointments.

Recent Drug Updates at DrugIndexOnline:





calamine topical calamine topical
Generic Name: calamine (topical) (KAL ih myn) Brand Names: Calamine Plain What is calamine? Calamine is used to treat itching and skin irritation caused by chicken pox, insect bites or stings, measles, eczema, sunburn, poison ivy, and other minor skin conditions. This medication may also more...

Captopril/Hydrochlorothiazide Captopril/Hydrochlorothiazide
Generic Name: Captopril/Hydrochlorothiazide (KAP-toe-prill/hye-droe-klor-oh-THYE-a-zide) Brand Name: CapozideWhen used after the third month of pregnancy, Captopril/Hydrochlorothiazide can cause injury and even death to the developing fetus. If you become pregnant or think you may be pregnant, more...

Flumadine Syrup Flumadine Syrup
Generic Name: Rimantadine Syrup (ri-MAN-ta-deen) Brand Name: FlumadineFlumadine Syrup is used for:Preventing and treating certain types of flu in adults. It is also used to prevent certain types of flu in children. It may also be used for other conditions as determined by your doctor. Flumadine more...

Hydroxyzine Hydroxyzine
Pronouncation: (high-DROX-ih-zeen) Class: Antianxiety, Piperazine, nonselective Trade Names: Hydroxyzine Hydrochloride - Tablets 10 mg - Tablets 25 mg - Tablets 50 mg - Tablets 100 mg - Syrup 10 mg per 5 mL - Injection 25 mg/mL Trade Names: Vistaril - Capsules 25 mg (as pamoate) - Capsules 50 mg (a more...

Marcaine Solution Marcaine Solution
Generic Name: Bupivacaine Injection Solution (byoo-PIV-a-kane) Brand Name: Examples include Marcaine and SensorcaineMarcaine Solution is used for:Numbing (loss of feeling) during dental or surgical procedures, labor, or delivery. It may also be used for other conditions as determined by your do more...

Metoclopramide Metoclopramide
Generic Name: Metoclopramide Tablets (meht-oh-KLOE-pra-mide) Brand Name: ReglanMetoclopramide is used for:Short term treatment of gastroesophageal reflux disease (GERD) in certain patients who do not respond to other therapy. It is used to treat symptoms of a certain digestive problem in diabet more...

Nadolol Nadolol
Some commonly used brand names are: In the U.S.— Betapace 13 Blocadren 14 Cartrol 5 Corgard 8 Inderal 12 Inderal LA 12 Kerlone 3 Levatol 10 Lopressor 7 Normodyne 6 Sectral 1 Tenormin 2 Toprol-XL 7 Trandate 6 Visken 11 Zebeta 4 In Canada— Apo-Atenolol 2 Apo-Metoprolol 7 Apo-Metopro more...

Neoptic Neoptic
Generic Name: gramicidin/neomycin/polymyxin B ophthalmic (gram i SEE din/nee oh MY sin/paw lee MIX in) Brand Names: AK-Spore, Neocidin, Neocin PG, Neoptic, Neosporin Ophthalmic What is Neoptic (gramicidin/neomycin/polymyxin B ophthalmic)? Gramicidin, neomycin, and polymyxin B are all an more...